2022 Control of Renal Function in Health & Disease: New Frontiers

2022健康和疾病中的肾功能控制：新前沿 项目总结/摘要 这个NIH R13赠款申请寻求支持即将到来的2022年会议的旅行奖励计划 题为"健康和疾病中的肾功能控制：新前沿"。美国生理学会 和美国肾脏病学会将赞助定于2022年6月26日至30日举行的会议 弗吉尼亚州夏洛茨维尔会议包括几个主要的翻译和治疗领域 与科学界相关的问题。近30%的美国人口患有高血压， 50%的高血压患者的血压得到控制。人类和动物的研究 表明高血压改变了肾脏调节盐和水稳态的能力，两者都受到 肾血流动力学和炎症介导的机制。因此，肾脏在肾脏疾病中起着关键作用。 它是高血压的发病机制，并且是进一步加重高血压的终末器官损伤的主要靶标。 此外，肥胖症、代谢综合征和糖尿病的日益流行导致了肥胖症、代谢综合征和糖尿病的大量增加。 慢性肾脏病（CKD）的发病率。最后，急性肾损伤（AKI）也在上升， 增加缺血和肾毒性事件。我们必须更好地了解肾损伤是如何发生的 由于高血压、CKD和AKI。在过去的5年里，出现了一些新的方法 开发用于研究肾功能和肾脏生理学家和肾脏病学家感兴趣的疾病 一模一样。因此，科学界非常需要召开一次以这些主题为重点的会议。的 组委会已经制定了一个会议计划，重点关注肾脏功能的新领域， 疾病，包括关于以下主题的研讨会：肥胖症，糖尿病和代谢综合征;炎症和 肾脏;肾脏疾病的发育规划;肾脏的遗传学、表观遗传学;免疫学和 肾脏，肾功能的昼夜节律生物学，肾脏疾病和类器官中的单细胞RNASEQ。专题讨论 还将涵盖肾血流动力学，急性肾损伤，综合治疗等传统领域的最新进展。 控制肾功能、慢性肾脏疾病、肾功能和高血压中的自体激素和营养。 为了提高受训人员和早期职业调查员对实地工作的兴趣， 会议上，我们建议管理一个NIH资助的旅行奖励计划的学员和早期的职业生涯 investigators.

2022 Control of Renal Function in Health and Disease: New Frontiers Project Summary/Abstract This NIH R13 grant application seek support for a travel award program for the upcoming 2022 conference entitled “Control of Renal Function in Health and Disease: New Frontiers”. The American Physiological Society and the American Society of Nephrology are sponsoring the conference which is scheduled for June 26-30, 2022 in Charlottesville, Virginia. There are several major translational and therapeutic areas included in the meeting that have relevance to the scientific community. Nearly 30% of the U.S. population has hypertension and only 50% of individuals with hypertension have their blood pressure controlled. Human and animal studies have shown that hypertension changes the kidney’s ability to regulate salt and water homeostasis, both affected by renal hemodynamic and inflammation-mediated mechanisms. Thus, the kidney plays a key role in the pathogenesis of hypertension and is a major target of end-organ-damage that further exacerbates hypertension. In addition, the growing epidemic of obesity, metabolic syndrome and diabetes has led to a large increase in the incidence of chronic kidney disease (CKD). Finally, acute kidney injury (AKI) is also on the rise as a result of increasing ischemic and nephrotoxic events. We must gain a better understanding as to how renal injury occurs as a result of hypertension, CKD, and AKI. In the last 5 years, there have been several novel methodologies developed to study kidney function and disease that would be of interest to renal physiologists and nephrologists alike. Thus, there is a great need in the scientific community for a conference focused on these topics. The organizing committee has developed a meeting program that focuses on novel areas of kidney function and disease including symposia on the following topics: obesity, diabetes and metabolic syndrome; inflammation and the kidney; developmental programming of kidney disease; genetics, epigenetics of the kidney; immunology and the kidney, circadian biology of kidney function, single cell RNASEQ in kidney disease and organoids. Symposia will also cover recent advances in traditional areas of renal hemodynamics, acute kidney injury, integrative control of kidney function, chronic kidney disease, autacoids and nutrition in kidney function and hypertension. In order to promote the interest of trainees and early career investigators in the field and their participation in the conference, we propose to administer an NIH-funded travel award program for trainees and early career investigators.